

REIMBURSEMENT REVIEW

Patient and Clinician Group Input

ferric carboxymaltose (TBC)
(CSL Vifor)

Indication: Ferinject (ferric carboxymaltose) is indicated: for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older when oral iron preparations are not tolerated or are ineffective. for the treatment of iron deficiency (ID) in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity. The diagnosis of iron deficiency must be based on laboratory tests.

May 14, 2024

This document compiles the input submitted by patient groups and clinician groups for the file under review. The information is used by CDA-AMC in all phases of the review, including the appraisal of evidence and interpretation of the results. The input submitted for each review is also included in the briefing materials that are sent to expert committee members prior to committee meetings.

Disclaimer: The views expressed in this submission are those of the submitting organization or individual. As such, they are independent of CDA-AMC and do not necessarily represent or reflect the views of CDA-AMC. No endorsement by CDA-AMC is intended or should be inferred.

By filing with CDA-AMC, the submitting organization or individual agrees to the full disclosure of the information. CDA-AMC does not edit the content of the submissions received.

CDA-AMC does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no identifying personal information or personal health information is included in the submission. The name of the submitting group and all conflicts of interest information from individuals who contributed to the content are included in the posted submission.

Patient Group Input

Gastrointestinal Society

About Gastrointestinal Society

The GI (Gastrointestinal) Society is committed to improving the lives of people with GI and liver conditions, supporting research, advocating for appropriate patient access to healthcare, and promoting gastrointestinal and liver health.

We are a national charity formed in 2008 on the groundwork of its partner organization, the Canadian Society of Intestinal Research (CSIR), which was founded in Vancouver in 1976. We receive national and international attention, simply because we have earned the respect of both the gastrointestinal medical community and Canadians who battle GI and liver issues daily. Our website (www.badgut.org) is available in both English and French and received 9,329,479 page views in 2023.

All our programs and services focus on providing Canadians with trusted, commercial-free, medically-sound information on gut (including obesity) and liver diseases and disorders in both official languages. Our BadGut® lectures, quarterly *Inside Tract*® newsletter, pamphlets, support groups, and educational [videos](#) arm Canadians with the information they require to better understand and manage their specific needs. We also work closely with healthcare professionals and governments at all levels toward system-wide improvements in care and treatment.

Information Gathering

We completed this submission by using information we obtained from meetings and discussions with healthcare professionals and researchers, as well as questionnaires and interviews from various surveys we conducted on digestive and liver diseases and disorders.

We are working with healthcare professionals to develop videos in both English and French on iron deficiency anemia (IDA), which will be available later in 2024. Currently, we have one available in English, featuring Dr. Jan Andre Grauman, a physician who specializes in treating IDA, available at <https://badgut.org/badgut-lecture-ida/>.



Disease Experience

Iron deficiency anemia (IDA) occurs when a person does not have enough healthy red blood cells to carry oxygen to the rest of the cells in their body. Iron deficiency can develop when our body loses iron from blood loss or bleeding, poor iron absorption in the gut, or if our body has difficulty making normal red blood cells.

Heavy menstrual periods, gastrointestinal bleeding (e.g., inflammatory bowel disease, stomach ulcers, hemorrhoids, gallstones), surgeries, pregnancy, childbirth, thyroid issues, and cancer are common causes of blood loss which can lead to IDA.

Poor iron absorption can arise from low iron diets, celiac disease, weight loss surgeries, heart failure, chronic kidney disease, inflammatory bowel disease (primarily Crohn's disease and ulcerative colitis), connective tissue conditions, or medications.

Some individuals are also born with conditions that make it difficult for their bodies to make normal red blood cells, such as abnormal production of hemoglobin, severe kidney problems, cancers, or bone marrow malfunction.

Dizziness, extreme fatigue, headaches, shortness of breath, tiredness, and muscle weakness are common and frequent symptoms of iron deficiency anemia. Other signs include extreme paleness, cold hands and feet, depression, and

cravings for things that are not food (pica), or having a poor appetite, especially in infants and children. Left untreated, iron deficiency anemia can lead to complications. Unborn babies can be affected by premature births, low birth weights, or permanent delayed growth and development.

Iron deficiency anemia can have significant effects on a person physically, mentally, financially, and socially. Since IDA often arises from a pre-existing condition, such as celiac disease and/or inflammatory bowel disease, many individuals must manage treating both conditions. IDA symptoms, especially extreme fatigue, can make it difficult to take part of daily activities, responsibilities, and social gatherings, leading many individuals to feel isolated. Research is also growing on the association between IDA and increased risk of mental health conditions.

The following are quotes from individuals living with inflammatory bowel disease describing how blood loss affects their quality of life:

- "It's like I can't control anything, I feel weak and can barely get up. My biggest concern is usually when I see blood and determining at what point to go to the ER."
- "Imagine trying to pass gas but along with it comes blood and mucous. You have loose stool six or more times a day with cramps so severe they make you nauseous. You're awakened every hour during the night from gas and cramps, and have to run to the toilet... My biggest concerns are how negatively the fatigue is affecting my life. I'm experiencing depression now, for the first time due to years of not sleeping properly."
- "Your gut aches and burns and there is often blood in the toilet. You lose your appetite and weight, unhealthily! My biggest concern is I'm going to run out of meds to help!"
- "The intense pain and rectal bleeding isn't something I even know how to explain. I've passed out standing up leaning over the sink from how intense the pain was and from losing so much blood."
- "My iron drops from bleeding, and I just don't absorb well at all. I would like to have IV hydration when needed when I'm really bad, but doctors don't seem to listen to me."

These individual stories, as summarized above, astound us, and motivate us to support the need for more diversity in accessible and effective treatments. These therapies should also improve quality of life, not cause more symptoms, pain, frustration, or hardship.

Experiences With Currently Available Treatments

There are several ways to manage IDA. These include dietary modifications, oral iron supplements, and intravenous iron infusions. Taking preventive steps are highly encouraged, and Canadian recommendations for the adequate intake of iron varies by age, gender, and whether women are pregnant or breastfeeding.

With treatments, oral iron supplements are the simplest and most accessible way to replenish iron stores and there are many different iron supplements available without the need for a prescription. They are available in varying doses and different iron salts contain different amounts of elemental iron (e.g., ferrous fumarate, ferrous sulfate, ferrous gluconate). However, some iron formulations might not be absorbed completely. Common side effects of oral iron products are constipation, stomach upset, nausea, vomiting, dark stools, or teeth staining from liquid iron products. Some individuals are also unable to absorb or tolerate oral iron well for several reasons (e.g., time constraints from surgery, pregnancy, or childbirth; malabsorption; intolerable side effects with oral iron).

There are newer oral iron supplement formulations, such as heme iron polypeptide (e.g., Proferrin®), iron complexed with polysaccharides (e.g., FeraMAX® polydextrose iron complex), and iron delivered by liposomes or phospholipids (e.g., Ferosom Forte LCE Liposomal™ Iron and Sucrosomial® Iron). These might improve absorption and have fewer side effects than the traditional iron salts.

Although there are many iron supplements available over-the-counter, several have various marketing claims that might not necessarily be true. Some might not have quality regulations in the manufacturing of the product, resulting in lower iron content, and others might not have the clinical experience to support their efficacy claims. These products can also incur high out-of-pocket costs for patients.

There are also intravenous (IV) iron infusions available. These are administered in a hospital outpatient clinic or private infusion clinic. High dose IV administration is the most effective option for people who have experienced significant blood loss or have very low iron levels as it can supply individuals with very large amounts of iron at once, allowing them to recover from symptoms more quickly. An example of a high dose IV iron is ferric derisomaltose (Monoferric®), and the infusion typically lasts 30 minutes.

However, IV iron carries some disadvantages with the infusion itself and infusion-related side effects. Individuals receiving IV iron might be asked to stay an extra 30 minutes after an infusion to monitor for allergies or adverse reactions. Some people also do not like the infusion process itself and having an IV put in. There is a risk for infusion-related side effects, although rare, and staining of the skin or veins with iron which can take six months or more to fade. Another risk for an infusion is having a fishbane reaction, which is a pseudoallergy that includes flushing of the skin and can cause temporary (about 15 minutes) muscle contractions. Since iron infusions require in-person appointments, they can be burdensome as patients need to take time off school or work and arrange transportation to get to the clinic.

There are low dose options as well, such as sodium ferric gluconate complex (Ferrlecit®) and iron sucrose (Venofer®). However, they generally require multiple (three or more) infusions of longer duration (2-3 hours) with 4-6 weeks in between sessions. Given the risks associated with infusions, doctors often recommend treatments that have higher doses of iron.

Improved Outcomes

Patients and their families and healthcare professionals need access to treatments that have higher doses of iron, are better absorbed, and have fewer side effects. Physicians have also informed us of the need for increased accessibility of IV iron since they are more effective alternatives to oral supplements in some patients.

Experience With Drug Under Review

Ferric carboxymaltose (Ferinject®) is an IV iron available as an alternative option for children older than 1 year of age and adults who have already tried oral iron and it did not work for them or they were not able to tolerate it. Having alternative treatment options is crucial, as every person is different and may have varying needs and preferences. While we have not spoken with individuals who have experience with Ferinject®, we know that it is one of very few IV options available for use among children. Other IV iron products, such as Monoferric®, Venofer®, and Ferrlecit® are only indicated for use in adults.

We are also aware of research findings that compared the efficacy of ferric carboxymaltose (Ferinject®) with ferric derisomaltose (Monoferric®) in a randomized controlled trial.¹ The study found that although both are effective in restoring iron among trial participants, there were higher incidences of hypophosphatemia among those who received ferric carboxymaltose compared to ferric derisomaltose. This risk is reflected in Health Canada's product monograph, as it acknowledged that the product may include serious side effects, such as hypophosphatemia, and listed health conditions that put an individual at greater risk for this side effect. Those at risk include individuals living with inflammatory bowel

¹ Emrich IE *et al.* Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOME aFers study. *BMC Medicine*. 2020;18:178. <https://doi.org/10.1186/s12916-020-01643-5>.

disease. However, it is still vital to have Ferinject® available as an alternative option for individuals, especially children, who are in need of effective iron therapies.

Companion Diagnostic Test

n/a

Anything Else?

No.

Conflict of Interest Declaration - Gastrointestinal Society

To maintain the objectivity and credibility of the CADTH reimbursement review process, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

Did you receive help from outside your patient group to complete this submission?

No.

Did you receive help from outside your patient group to collect or analyze data used in this submission?

No.

Table 1: Financial Disclosures

Check Appropriate Dollar Range With an X. Add additional rows if necessary.

Company	\$0 to 5,000	\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000
n/a				

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Jaymee Maaghop

Position: Health Policy and Outreach Manager

Patient Group: Gastrointestinal Society

Date: 2024-05-08

Clinician Group Input

CADTH Project Number: SR0842-000 and SR0852-000

Generic Drug Name (Brand Name): Ferric carboxymaltose (Ferinject)

Indication: Treatment of:

- Iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older when oral iron preparations are not tolerated or are ineffective.
- Iron deficiency (ID) in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity.

About Your Clinician Group

Given ID and IDA affect many patient populations, we have assembled a group of independent clinicians from multiple specialties to provide feedback.

Table 1: List of participants

First name	Last name	Areas of expertise
Shelley	Zieroth	Cardiologist
Gordon	Moe	Cardiologist
Ally	Murji	Gynecology/Obstetrics
Ann Kinga	Malinowski	Gynecology/Obstetrics
Heather	Vandermeulen	Hematologist
Kevin	Pottie	Primary care
Andrea	Lavoie	Cardiology
Anil	Gupta	Cardiology
Eileen	O'Meara	Cardiologist
Brian	Bressler	Gastroenterology
Neeraj	Narula	Gastroenterology
Louise	Moist	Nephrologist
Gordon	Moe	Cardiologist

Information Gathering

Product monograph, published literature, and personal experience.

Current Treatments and Treatment Goals

Iron deficiency (ID) occurs on a continuum and, if left untreated, will eventually progress to iron deficiency anemia (IDA). ID can develop across a spectrum of conditions and states that cause increased losses and/or decreased absorption, including heart failure (HF), chronic kidney disease (CKD), inflammatory bowel disease (IBD), heavy menstrual bleeding (HMB), and pregnancy, among others. ID can also be precipitated or aggravated by iron-poor nutrition, as may be the case in an otherwise well pediatric patient.

In the Canadian context, ID and IDA are common, affecting approximately 7% and 2% of the population, respectively, with higher rates in females than males. Even in the absence of anemia, ID affects patients' physical and cognitive performance. For patients suffering from comorbid medical conditions, ID and IDA introduce additional burdens, exacerbating symptoms, accelerating disease progression, and worsening prognosis.

The key goals in the treatment of ID and IDA are the correction of the hemoglobin (Hb) deficit and repletion of iron stores, as well as the maintenance of iron stores over time. Correction is achieved using supplementation (either oral or intravenous [IV] iron products), whereas maintenance is often dependent on identifying and managing the underlying cause of ID. Treatment reduces symptoms and improves function, improving health-related quality of life.

The typical recommendations for the treatment of ID and IDA are to start with oral iron replacement, and, if this is unsuccessful, move to IV iron therapy. Oral iron is relatively safe, effective, and inexpensive. However, correction of IDA with oral iron is slow: treatment with ferrous salts (100–200 mg/day of elemental iron) may take up to 3 months to normalize Hb and replenish stores. A variety of oral iron supplements are available in Canada, with inconsistent evidence that newer, more expensive formulations (ie, iron polysaccharide complex or heme iron polypeptide) have fewer adverse effects than ferrous salts. Gastrointestinal (GI) side effects, in particular, are common and can have a detrimental impact on patient adherence to treatment.² Oral iron may also be ineffective for patients with GI tract impairment, chronic inflammatory conditions, or concomitant medication(s) that decrease absorption.

The notable exception to the recommendation to start with oral iron is in patients with HF, where ID prevalence reaches 50% and has been found to be an independent predictor of worse functional capacity, increased hospitalization, and mortality. These findings have prompted recommendations, including by the Heart Failure Society of America (HFSA) that IV iron is the preferred treatment for patients with HF (foregoing oral iron as first-line treatment), and that treatment begins when ID is recognized—regardless of whether IDA is present.^{3,4} This distinguishes HF from other conditions that typically suggest treatment only once the state of IDA is reached.

IV supplementation can also rapidly deliver iron to patients unable to absorb sufficient amounts from the GI tract, unable to tolerate the required dose, and/or who require faster repletion. In addition, the IV administration route can benefit patients with chronic losses exceeding the replacement rate possible with oral iron, and/or receiving erythropoietin-stimulating agent (ESA) treatment leading to increased iron demands. Last, IV iron can facilitate repletion in patients with poor adherence to oral products, as the total required iron amount can be delivered in one or two doses.

In addition to ferric carboxymaltose (FCM), there are currently four other IV iron products approved in Canada: Ferrlecit® (sodium ferric gluconate complex in sucrose; 12.5 mg/mL), Monoferric® (ferric derisomaltose; 100 mg/mL), Venofer® (iron sucrose; 20 mg/mL), and pms-Iron Sucrose® (iron sucrose injection; 20 mg/mL).

Treatment Gaps (unmet needs)

4.1. Considering the treatment goals in Section 3, please describe goals (needs) that are not being met by currently available treatments.

Most of the IV iron products previously available in Canada required administration over a long period of time and/or with a series of sessions to attain a cumulative dose of 1000 mg. Further, none were indicated for use in pediatric populations or for the treatment of patients with ID and HF.

FCM can safely deliver high doses (up to 1000 mg) of iron as a single injection or infusion over 15 minutes (and in less time for lower doses). As such, substantial gains in convenience and reductions in costs may be achieved for both patients and healthcare systems, with fewer individual administrations and reduced need for multiple, long treatment visits. A streamlined administration

² Samantha Moe, Allan K. Grill and G. Michael Allan. Newer iron supplements for anemia. *Canadian Family Physician* August 2019, 65 (8) 556. <https://www.cfp.ca/content/65/8/556>

³ Salah, H. M., Savarese, G., Rosano, G. M. C., Ambrosy, A. P., Mentz, R. J., and Fudim, M. (2023) Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. *ESC Heart Failure*, 10: 1473–1480. <https://doi.org/10.1002/ehf2.14310>.

⁴ Ponikowski P, Mentz RJ, Hernandez AF, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. *Eur Heart J*. 2023;44(48):5077-5091. doi:10.1093/eurheartj/ehad586

schedule may also improve adherence and, as a result, achievement of treatment goals. Further, high-dose IV iron delivery allows for rapid relief of symptoms due to faster correction of the deficiency.

Compared to older IV iron products, newer products, such as FCM, have better safety profiles. These formulations have complex carbohydrate cores that bind elemental iron more tightly and release it more slowly.⁵ They also use carbohydrate fragments with reduced immunogenic activity, which lowers the risk of severe hypersensitivity reactions.⁶ Additionally, the pH of FCM is physiologic, as is the osmolality/osmolality of the dispersion. Thus, FCM may have distinct advantages over the previously available IV iron compounds and may fill a clear unmet medical need for IV iron products with fast administration time.

Place in Therapy

5.1. How would the drug under review fit into the current treatment paradigm?

FCM offers an additional IV iron formulation for patients with ID and IDA when oral iron preparations are not tolerated or are ineffective. FCM may also be administered, without a trial of oral iron, in clinical situations where there is a need for rapid iron delivery.

FCM is likely to be used in place of IV iron products that require administration over a long time period and/or a series of sessions to attain a cumulative dose of 1000 mg (ie, sodium ferric gluconate complex in sucrose and iron sucrose). FCM may also be used in place of ferric derisomaltose, as both products offer the ability to deliver high doses (1000 mg) of iron over short periods of time (30 minutes for ferric derisomaltose and 15 minutes for FCM, respectively). The ability to deliver a high dose in a single session is particularly valuable when urgent correction of anemia and repletion of iron stores is required.

FCM will be used for the same clinical indications as the other IV iron products. In addition, while other products may be used off-label, FCM is the only IV iron indicated for the pediatric population in Canada. Finally, FCM is the first IV iron with a specific indication in patients with HF to address the ID that reduces exercise capacity in this chronically inflamed population.

5.2. Which patients would be best suited for treatment with the drug under review? Which patients would be least suitable for treatment with the drug under review?

Most adult and pediatric patients 1 year of age and older with IDA are well suited for treatment with FCM when oral iron preparations are not tolerated or are ineffective. These patients are expected to respond and to do so rapidly. While repletion of iron stores with oral products may require administration over several months, correction following FCM treatment occurs within days to weeks. Most patients will also appreciate that FCM treatment is administered over a shorter infusion time and in fewer visits compared to most other IV iron products; these product features will be even more important to patients with higher iron needs and/or who experience economic consequences from limited work tolerance due to unresolved IDA. For example, women of reproductive age from immigrant, refugee, and other migrant populations may face less barriers in caring for their (often large) families if IDA can be rapidly corrected.

Further, patients with HF and ID are well suited for treatment, as ID in these patients is known to be particularly resistant to oral iron therapy, necessitating the need for IV iron supplementation. Since ID is an independent predictor of reduced functional capacity, increased hospitalization, and increased mortality for HF patients, guidelines from the Canadian Cardiovascular Society, the HFSA, and the European Society of Cardiology (ESC) all recommend starting patients with IV iron in preference to oral formulations—regardless of whether anemia is present. The recently updated ESC guideline for the diagnosis and treatment of chronic and acute HF specifically recommends FCM as a treatment for symptomatic HF patients with ID. Similarly, recent guidelines from the American

⁵ Layla Van Doren, Michael Auerbach; IV iron formulations and use in adults. *Hematology Am Soc Hematol Educ Program* 2023; 2023 (1): 622–629. doi: <https://doi.org/10.1182/hematology.2023000495>

⁶ Blumenstein, I., Shanbhag, S., Langguth, P., Kalra, P. A., Zoller, H., & Lim, W. (2021). Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety. *Expert Opinion on Drug Safety*, 20(7), 757–769. <https://doi.org/10.1080/14740338.2021.1912010>

College of Cardiology (ACC) recommend that in patients with HF with reduced ejection fraction (HFrEF) and ID with or without anemia, IV iron replacement is reasonable to improve functional status and quality of life.^{7,8}

Limited clinical evidence also suggests that FCM is safe for use in pregnant patients. In obstetrics, IV iron infusions are often used to treat IDA, before and after delivery. However, prior to the introduction of FCM, a high dose IV iron formulation was not available for use during pregnancy in Canada (per the product monograph, ferric derisomaltose should not be used). As such, the addition of FCM as a treatment option for IDA in pregnancy—with all its advantages over low dose IV iron—is eagerly anticipated, especially by prescribers who have previously used the product in Europe, where it has been approved for almost two decades. It is also expected that the availability of FCM will lead to updated guidelines for the treatment of IDA in this population.

Patients suited for treatment with FCM can be identified using routine laboratory testing (ie, complete blood count, serum ferritin, \pm transferrin saturation [TSAT]). For patients with HF, the simple and widely used New York Heart Association (NYHA) class subjectively estimates functional ability.

As ferritin levels can be elevated in patients with inflammation, ID may be underdiagnosed if ferritin alone is used for diagnosis. For these patients, TSAT is an important marker, with a value $<20\%$ indicative of low plasma iron availability to tissues in both absolute and functional ID.

5.3 What outcomes are used to determine whether a patient is responding to treatment in clinical practice? How often should treatment response be assessed?

In both clinical practice and clinical trials, hematologic response and iron parameters (ferritin and TSAT), are used to determine whether a patient is responding to treatment. Ideally, patients would experience normalization of their Hb, such that they are no longer anemic. Further, ferritin would rise to levels above those diagnostic of ID. The expected magnitude of the response will vary depending on the patient, recognizing that complete correction may not be possible due to comorbidities and/or ongoing blood loss. In these patients—and all treated patients—it is also clinically meaningful for other outcomes to be achieved, for example, avoiding blood transfusion, improving symptoms, increasing exercise capacity, enhancing quality of life, or reducing hospitalizations.

Response to treatment should be regularly monitored during treatment. In clinical practice, this typically occurs 4–8 weeks after the completion of the initial treatment course. Laboratory assays may overestimate serum iron and transferrin-bound iron in the 24 hours following FCM administration.

5.4 What factors should be considered when deciding to discontinue treatment with the drug under review?

Post-iron repletion assessments (Hb, ferritin, \pm TSAT) are considered when deciding to discontinue treatment with FCM. Reassessment should be performed no earlier than 4 weeks after the final dose to allow adequate time for erythropoiesis and iron utilization.

Some patients are more likely to require additional treatment including those with lower initial Hb, impaired parenteral iron absorption (eg, IBD or post bariatric surgery), ongoing blood losses (eg, HMB or CKD requiring hemodialysis), and comorbid chronic inflammation (eg, CHF).

Treatment should be stopped immediately in patients with hypersensitivity reactions or signs of intolerance during administration. Treatment should not be administered to patients with iron overload. Treatment should be re-evaluated in patients with persistent hypophosphatemia.

⁷ Salah, H. M., Savarese, G., Rosano, G. M. C., Ambrosy, A. P., Mentz, R. J., and Fudim, M. (2023) Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. *ESC Heart Failure*, 10: 1473–1480. <https://doi.org/10.1002/ehf2.14310>.

⁸ Ponikowski P, Mentz RJ, Hernandez AF, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. *Eur Heart J*. 2023;44(48):5077-5091. doi:10.1093/eurheartj/ehad586

5.5 What settings are appropriate for treatment with [drug under review]? Is a specialist required to diagnose, treat, and monitor patients who might receive [drug under review]?

Appropriate settings for treatment with FCM are those where personnel and therapies are available for the treatment of anaphylaxis and other hypersensitivity reactions. In practice, this will often be hospital day units or infusion clinics attended by outpatients. Where facilities exist, FCM may be administered in the community, at clinics and pharmacies that provide infusion services. If treatment is indicated, the emergency department or surgical inpatient unit are also appropriate settings for treatment.

A specialist is not required to diagnose, treat, and monitor patients who might receive FCM. In addition to family medicine and hematology, several specialties need to use IV iron in their practice, including cardiologists, gastroenterologists, internists, nephrologists, and obstetricians/gynecologists; midwives and nurse practitioners may also manage ID and IDA.⁹ However, as hospital privileges are necessary to order IV iron within that setting, specialists will most commonly prescribe FCM.

Additional Information

Another consideration is that in Canada, there have been recent shortages of prescription drugs, with over 2,700 reports were received by Health Canada during the 2022–2023 period. Drug shortages can negatively affect patient treatment plans.¹⁰ The availability of a second option for high dose IV iron in case of a shortage would provide a safeguard against harmful treatment interruptions.

⁹INESSS. Avril 2022. Traitement au fer intraveineux chez l'adulte Rapport en soutien au protocole médical national et au modèle d'ordonnance individuelle préimprimée.

https://www.inesss.qc.ca/fileadmin/doc/INESSS/Ordonnances_collectives/Fer_intraveineux/INESSS_Traitement_fer_IV_GN.pdf

¹⁰ Huyghebaert T, Svrcek C, Perry TL. How to navigate drug shortages with patients in primary care. Beneficial opportunities may exist beyond initial frustrations. 2024;70(2):85-86. doi:10.46747/cfp.700285

Conflict of Interest Declarations – Clinician Group

To maintain the objectivity and credibility of the CADTH drug review programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This conflict of interest declaration is required for participation. Declarations made do not negate or preclude the use of the clinician group input. CADTH may contact your group with further questions, as needed. Please see the [Procedures for CADTH Drug Reimbursement Reviews](#) (section 6.3) for further details.

Did you receive help from outside your clinician group to complete this submission? If yes, please detail the help and who provided it.

International Market Access Consulting (IMAC) assisted in a supportive role: specifically collected physicians' conflict of interest declarations.

Did you receive help from outside your clinician group to collect or analyze any information used in this submission? If yes, please detail the help and who provided it.

International Market Access Consulting (IMAC) provided background information in a supportive role.

List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review. **Please note that this is required for each clinician who contributed to the input — please add more tables as needed (copy and paste). It is preferred for all declarations to be included in a single document.**

Declaration for Clinician 1

Name: Dr. Shelley Zieroth

Position: Professor of Medicine

Date: 07-05-2024

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this clinician or clinician group with a company, organization, or entity that may place this clinician or clinician group in a real, potential, or perceived conflict of interest situation.

Table 1: Conflict of Interest Declaration for Clinician 1

Company	Check appropriate dollar range*			
	\$0 to \$5,000	\$5,001 to \$10,000	\$10,001 to \$50,000	In excess of \$50,000
CSL/Vifor	X			

* Place an X in the appropriate dollar range cells for each company.

Declaration for Clinician 2

Name: Dr. Louise Moist

Position: Nephrologist

Date: 01-05-2024

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this clinician or clinician group with a company, organization, or entity that may place this clinician or clinician group in a real, potential, or perceived conflict of interest situation.

Table 2: Conflict of Interest Declaration for Clinician 2

Company	Check appropriate dollar range*			
	\$0 to \$5,000	\$5,001 to \$10,000	\$10,001 to \$50,000	In excess of \$50,000
Bayer		X		
Lilly		X		
BI		X		
Otsuka		X		

* Place an X in the appropriate dollar range cells for each company.

Declaration for Clinician 3

Name: Dr. Kevin Pottie

Position: Family Physician Researcher> – Dalhousie University

Date: 01-05-2024

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this clinician or clinician group with a company, organization, or entity that may place this clinician or clinician group in a real, potential, or perceived conflict of interest situation.

Table 3: Conflict of Interest Declaration for Clinician 3

Company	Check appropriate dollar range*			
	\$0 to \$5,000	\$5,001 to \$10,000	\$10,001 to \$50,000	In excess of \$50,000
CSL Vifor	X			

* Place an X in the appropriate dollar range cells for each company.

Declaration for Clinician 4

Name: Dr. Brian Bressler

Position: Staff Gastroenterologist

Date: 30-04-2024

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this clinician or clinician group with a company, organization, or entity that may place this clinician or clinician group in a real, potential, or perceived conflict of interest situation.

Table 4: Conflict of Interest Declaration for Clinician 4

Company	Check appropriate dollar range*			
	\$0 to \$5,000	\$5,001 to \$10,000	\$10,001 to \$50,000	In excess of \$50,000
Celltrion	X			
Sandoz	X			
Eli Lilly	X			
Organon		X		
BMS		X		
Gilead		X		
Viartis		X		
Takeda				X
Abbvie				X
Janssen				X
Pfizer				X
Alimentiv				X

* Place an X in the appropriate dollar range cells for each company.

Declaration for Clinician 5

Name: Dr. Gordon Moe

Position: Cardiologist, Director Heart Failure Program

Date: 06-05-2024

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this clinician or clinician group with a company, organization, or entity that may place this clinician or clinician group in a real, potential, or perceived conflict of interest situation.

Table 5: Conflict of Interest Declaration for Clinician 5

Company	Check appropriate dollar range*			
	\$0 to \$5,000	\$5,001 to \$10,000	\$10,001 to \$50,000	In excess of \$50,000
None				

* Place an X in the appropriate dollar range cells for each company.

Declaration for Clinician 6

Name: Dr. Ann Malinowski

Position: Maternal-Fetal Medicine Specialist

Date: 27-04-2024

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this clinician or clinician group with a company, organization, or entity that may place this clinician or clinician group in a real, potential, or perceived conflict of interest situation.

Table 5: Conflict of Interest Declaration for Clinician 6

Company	Check appropriate dollar range*			
	\$0 to \$5,000	\$5,001 to \$10,000	\$10,001 to \$50,000	In excess of \$50,000
CSF Vifor	X			

* Place an X in the appropriate dollar range cells for each company

Declaration for Clinician 7

Name: Dr. Neeraj Narula

Position: Director of IBD Clinic at Hamilton Health Sciences

Date: 28-04-2024

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this clinician or clinician group with a company, organization, or entity that may place this clinician or clinician group in a real, potential, or perceived conflict of interest situation.

Table 5: Conflict of Interest Declaration for Clinician 7

Company	Check appropriate dollar range*			
	\$0 to \$5,000	\$5,001 to \$10,000	\$10,001 to \$50,000	In excess of \$50,000
Abbvie			X	
Janssen		X		
Takeda		X		
Eli Lilly	X			
Fresenius Kabi	X			
Pfizer		X		
Viartis	X			
Sandoz	X			
Iterative Health			X	
Innomar Strategies		X		

* Place an X in the appropriate dollar range cells for each company

Declaration for Clinician 8

Name: Dr. Mark Belletrutti

Position: Director of IBD Clinic at Hamilton Health Sciences

Date: 29-04-2024

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this clinician or clinician group with a company, organization, or entity that may place this clinician or clinician group in a real, potential, or perceived conflict of interest situation.

Table 5: Conflict of Interest Declaration for Clinician 8

Company	Check appropriate dollar range*			
	\$0 to \$5,000	\$5,001 to \$10,000	\$10,001 to \$50,000	In excess of \$50,000
Roche Canada		X		
Sanofi Canada		X		
Octapharma Canada	X			
Novo Nordisk Canada	X			
Bayer Canada	X			

* Place an X in the appropriate dollar range cells for each company

Declaration for Clinician 9

Name: Dr. Eileen O'Meara

Position: Cardiologist - Montreal Heart Institute

Date: 29-04-2024

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this clinician or clinician group with a company, organization, or entity that may place this clinician or clinician group in a real, potential, or perceived conflict of interest situation.

Table 5: Conflict of Interest Declaration for Clinician 9

Company	Check appropriate dollar range*			
	\$0 to \$5,000	\$5,001 to \$10,000	\$10,001 to \$50,000	In excess of \$50,000
American Regent**	N/A	N/A	N/A	N/A

* Place an X in the appropriate dollar range cells for each company

**All fees related to the Heart-FID trial were paid to my institutions HF research group.

Conflict of Interest Disclosures

- **Grants/research support*:** The Montreal Heart Institute's Carolyn & Richard J. Renaud Chair for Research in Heart Failure, with fees paid through her institution for this Chair and for the following: Canadian Heart Function Alliance (CHFA) Team Grant, funded by the CIHR (SC member), and involvement in the following trials as a SC member for DAPA-ACT (TIMI group and AZ) and GARDEN-HF (TIMI group and Pfizer), for HEART-FID (SC member, American Regent), CARDINAL-HF (SC member, Cardurion), HERMES (NLI, Novo Nordisk), and BalancedD-HF (NLI, AZ)
- **Consulting fees:** Astra Zeneca, Boehringer Ingelheim, Bayer, Novartis, Novo Nordisk
- **Speaker fees:** Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Novo Nordisk, Pfizer

* Note: all research support is directed to the care of the MHI HF team at the MHI Research Center